| UTHEALTH HOME ABOUT SBMI A-Z WEBMAIL INSIDE THE UNIVERSITY |
|
|||||||
|
Fusion Protein:SSBP2-JAK2 |
Fusion Protein Summary |
 Fusion gene summary |
| Fusion partner gene information | Fusion gene name: SSBP2-JAK2 | FusionPDB ID: 86711 | FusionGDB2.0 ID: 86711 | Hgene | Tgene | Gene symbol | SSBP2 | JAK2 | Gene ID | 23635 | 3717 |
| Gene name | single stranded DNA binding protein 2 | Janus kinase 2 | |
| Synonyms | HSPC116|SOSS-B2 | JTK10|THCYT3 | |
| Cytomap | 5q14.1 | 9p24.1 | |
| Type of gene | protein-coding | protein-coding | |
| Description | single-stranded DNA-binding protein 2sequence-specific single-stranded-DNA-binding protein 2 | tyrosine-protein kinase JAK2JAK-2Janus kinase 2 (a protein tyrosine kinase) | |
| Modification date | 20200313 | 20200329 | |
| UniProtAcc | P81877 | O60674 | |
| Ensembl transtripts involved in fusion gene | ENST ids | ENST00000320672, ENST00000505980, ENST00000509053, ENST00000514493, ENST00000515395, ENST00000510060, | ENST00000381652, ENST00000487310, ENST00000539801, ENST00000544510, |
| Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0) | * DoF score | 12 X 13 X 6=936 | 22 X 26 X 9=5148 |
| # samples | 14 | 15 | |
| ** MAII score | log2(14/936*10)=-2.74108170263844 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(15/5148*10)=-5.10097764772482 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
| Context (manual curation of fusion genes in FusionPDB) | PubMed: SSBP2 [Title/Abstract] AND JAK2 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0) | |||
| Anticipated loss of major functional domain due to fusion event. | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Tgene | JAK2 | GO:0010811 | positive regulation of cell-substrate adhesion | 10925297 |
| Tgene | JAK2 | GO:0019221 | cytokine-mediated signaling pathway | 8609418 |
| Tgene | JAK2 | GO:0033209 | tumor necrosis factor-mediated signaling pathway | 8609418 |
| Tgene | JAK2 | GO:0034612 | response to tumor necrosis factor | 8609418 |
| Tgene | JAK2 | GO:0035409 | histone H3-Y41 phosphorylation | 19783980 |
| Tgene | JAK2 | GO:0035722 | interleukin-12-mediated signaling pathway | 7528775 |
| Tgene | JAK2 | GO:0046677 | response to antibiotic | 16280321 |
| Tgene | JAK2 | GO:0050727 | regulation of inflammatory response | 10925297 |
| Tgene | JAK2 | GO:0060396 | growth hormone receptor signaling pathway | 10925297 |
| Tgene | JAK2 | GO:0070671 | response to interleukin-12 | 7528775 |
| Fusion gene breakpoints across SSBP2 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Fusion gene breakpoints across JAK2 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Top |
Fusion Gene Sample Information |
| Fusion gene information from FusionGDB2.0. |
| Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ChimerKB3 | . | . | SSBP2 | chr5 | 80809446 | - | JAK2 | chr9 | 5069021 | + |
| ChimerKB3 | . | . | SSBP2 | chr5 | 80932375 | - | JAK2 | chr9 | 52731680 | + |
Top |
Fusion ORF Analysis |
| Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
| ENST00000320672 | SSBP2 | chr5 | 80809446 | - | ENST00000539801 | JAK2 | chr9 | 5069021 | + | 2679 | 583 | 211 | 2655 | 814 |
| ENST00000320672 | SSBP2 | chr5 | 80809446 | - | ENST00000381652 | JAK2 | chr9 | 5069021 | + | 4048 | 583 | 211 | 2655 | 814 |
| ENST00000320672 | SSBP2 | chr5 | 80809446 | - | ENST00000544510 | JAK2 | chr9 | 5069021 | + | 2714 | 583 | 211 | 2655 | 814 |
| ENST00000505980 | SSBP2 | chr5 | 80809446 | - | ENST00000539801 | JAK2 | chr9 | 5069021 | + | 2473 | 377 | 5 | 2449 | 814 |
| ENST00000505980 | SSBP2 | chr5 | 80809446 | - | ENST00000381652 | JAK2 | chr9 | 5069021 | + | 3842 | 377 | 5 | 2449 | 814 |
| ENST00000505980 | SSBP2 | chr5 | 80809446 | - | ENST00000544510 | JAK2 | chr9 | 5069021 | + | 2508 | 377 | 5 | 2449 | 814 |
| DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
Top |
Fusion Amino Acid Sequences |
| For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
| >FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP >86711_86711_1_SSBP2-JAK2_SSBP2_chr5_80809446_ENST00000320672_JAK2_chr9_5069021_ENST00000381652_length(amino acids)=814AA_BP=123 MYGKGKSNSSAVPSDSQAREKLALYVYEYLLHVGAQKSAQTFLSEIRWEKNITLGEPPGFLHSWWCVFWDLYCAAPERRETCEHSSEAKA FHDYSAAAAPSPVLGNIPPGDGMPVGPVPPGFFQRENVIEYKHCLITKNENEEYNLSGTKKNFSSLKDLLNCYQMETVRSDNIIFQFTKC CPPKPKDKSNLLVFRTNGVSDVPTSPTLQRPTHMNQMVFHKIRNEDLIFNESLGQGTFTKIFKGVRREVGDYGQLHETEVLLKVLDKAHR NYSESFFEAASMMSKLSHKHLVLNYGVCVCGDENILVQEFVKFGSLDTYLKKNKNCINILWKLEVAKQLAWAMHFLEENTLIHGNVCAKN ILLIREEDRKTGNPPFIKLSDPGISITVLPKDILQERIPWVPPECIENPKNLNLATDKWSFGTTLWEICSGGDKPLSALDSQRKLQFYED RHQLPAPKWAELANLINNCMDYEPDFRPSFRAIIRDLNSLFTPDYELLTENDMLPNMRIGALGFSGAFEDRDPTQFEERHLKFLQQLGKG NFGSVEMCRYDPLQDNTGEVVAVKKLQHSTEEHLRDFEREIEILKSLQHDNIVKYKGVCYSAGRRNLKLIMEYLPYGSLRDYLQKHKERI DHIKLLQYTSQICKGMEYLGTKRYIHRDLATRNILVENENRVKIGDFGLTKVLPQDKEYYKVKEPGESPIFWYAPESLTESKFSVASDVW SFGVVLYELFTYIEKSKSPPAEFMRMIGNDKQGQMIVFHLIELLKNNGRLPRPDGCPDEIYMIMTECWNNNVNQRPSFRDLALRVDQIRD -------------------------------------------------------------- >86711_86711_2_SSBP2-JAK2_SSBP2_chr5_80809446_ENST00000320672_JAK2_chr9_5069021_ENST00000539801_length(amino acids)=814AA_BP=123 MYGKGKSNSSAVPSDSQAREKLALYVYEYLLHVGAQKSAQTFLSEIRWEKNITLGEPPGFLHSWWCVFWDLYCAAPERRETCEHSSEAKA FHDYSAAAAPSPVLGNIPPGDGMPVGPVPPGFFQRENVIEYKHCLITKNENEEYNLSGTKKNFSSLKDLLNCYQMETVRSDNIIFQFTKC CPPKPKDKSNLLVFRTNGVSDVPTSPTLQRPTHMNQMVFHKIRNEDLIFNESLGQGTFTKIFKGVRREVGDYGQLHETEVLLKVLDKAHR NYSESFFEAASMMSKLSHKHLVLNYGVCVCGDENILVQEFVKFGSLDTYLKKNKNCINILWKLEVAKQLAWAMHFLEENTLIHGNVCAKN ILLIREEDRKTGNPPFIKLSDPGISITVLPKDILQERIPWVPPECIENPKNLNLATDKWSFGTTLWEICSGGDKPLSALDSQRKLQFYED RHQLPAPKWAELANLINNCMDYEPDFRPSFRAIIRDLNSLFTPDYELLTENDMLPNMRIGALGFSGAFEDRDPTQFEERHLKFLQQLGKG NFGSVEMCRYDPLQDNTGEVVAVKKLQHSTEEHLRDFEREIEILKSLQHDNIVKYKGVCYSAGRRNLKLIMEYLPYGSLRDYLQKHKERI DHIKLLQYTSQICKGMEYLGTKRYIHRDLATRNILVENENRVKIGDFGLTKVLPQDKEYYKVKEPGESPIFWYAPESLTESKFSVASDVW SFGVVLYELFTYIEKSKSPPAEFMRMIGNDKQGQMIVFHLIELLKNNGRLPRPDGCPDEIYMIMTECWNNNVNQRPSFRDLALRVDQIRD -------------------------------------------------------------- >86711_86711_3_SSBP2-JAK2_SSBP2_chr5_80809446_ENST00000320672_JAK2_chr9_5069021_ENST00000544510_length(amino acids)=814AA_BP=123 MYGKGKSNSSAVPSDSQAREKLALYVYEYLLHVGAQKSAQTFLSEIRWEKNITLGEPPGFLHSWWCVFWDLYCAAPERRETCEHSSEAKA FHDYSAAAAPSPVLGNIPPGDGMPVGPVPPGFFQRENVIEYKHCLITKNENEEYNLSGTKKNFSSLKDLLNCYQMETVRSDNIIFQFTKC CPPKPKDKSNLLVFRTNGVSDVPTSPTLQRPTHMNQMVFHKIRNEDLIFNESLGQGTFTKIFKGVRREVGDYGQLHETEVLLKVLDKAHR NYSESFFEAASMMSKLSHKHLVLNYGVCVCGDENILVQEFVKFGSLDTYLKKNKNCINILWKLEVAKQLAWAMHFLEENTLIHGNVCAKN ILLIREEDRKTGNPPFIKLSDPGISITVLPKDILQERIPWVPPECIENPKNLNLATDKWSFGTTLWEICSGGDKPLSALDSQRKLQFYED RHQLPAPKWAELANLINNCMDYEPDFRPSFRAIIRDLNSLFTPDYELLTENDMLPNMRIGALGFSGAFEDRDPTQFEERHLKFLQQLGKG NFGSVEMCRYDPLQDNTGEVVAVKKLQHSTEEHLRDFEREIEILKSLQHDNIVKYKGVCYSAGRRNLKLIMEYLPYGSLRDYLQKHKERI DHIKLLQYTSQICKGMEYLGTKRYIHRDLATRNILVENENRVKIGDFGLTKVLPQDKEYYKVKEPGESPIFWYAPESLTESKFSVASDVW SFGVVLYELFTYIEKSKSPPAEFMRMIGNDKQGQMIVFHLIELLKNNGRLPRPDGCPDEIYMIMTECWNNNVNQRPSFRDLALRVDQIRD -------------------------------------------------------------- >86711_86711_4_SSBP2-JAK2_SSBP2_chr5_80809446_ENST00000505980_JAK2_chr9_5069021_ENST00000381652_length(amino acids)=814AA_BP=123 MYGKGKSNSSAVPSDSQAREKLALYVYEYLLHVGAQKSAQTFLSEIRWEKNITLGEPPGFLHSWWCVFWDLYCAAPERRETCEHSSEAKA FHDYSAAAAPSPVLGNIPPGDGMPVGPVPPGFFQRENVIEYKHCLITKNENEEYNLSGTKKNFSSLKDLLNCYQMETVRSDNIIFQFTKC CPPKPKDKSNLLVFRTNGVSDVPTSPTLQRPTHMNQMVFHKIRNEDLIFNESLGQGTFTKIFKGVRREVGDYGQLHETEVLLKVLDKAHR NYSESFFEAASMMSKLSHKHLVLNYGVCVCGDENILVQEFVKFGSLDTYLKKNKNCINILWKLEVAKQLAWAMHFLEENTLIHGNVCAKN ILLIREEDRKTGNPPFIKLSDPGISITVLPKDILQERIPWVPPECIENPKNLNLATDKWSFGTTLWEICSGGDKPLSALDSQRKLQFYED RHQLPAPKWAELANLINNCMDYEPDFRPSFRAIIRDLNSLFTPDYELLTENDMLPNMRIGALGFSGAFEDRDPTQFEERHLKFLQQLGKG NFGSVEMCRYDPLQDNTGEVVAVKKLQHSTEEHLRDFEREIEILKSLQHDNIVKYKGVCYSAGRRNLKLIMEYLPYGSLRDYLQKHKERI DHIKLLQYTSQICKGMEYLGTKRYIHRDLATRNILVENENRVKIGDFGLTKVLPQDKEYYKVKEPGESPIFWYAPESLTESKFSVASDVW SFGVVLYELFTYIEKSKSPPAEFMRMIGNDKQGQMIVFHLIELLKNNGRLPRPDGCPDEIYMIMTECWNNNVNQRPSFRDLALRVDQIRD -------------------------------------------------------------- >86711_86711_5_SSBP2-JAK2_SSBP2_chr5_80809446_ENST00000505980_JAK2_chr9_5069021_ENST00000539801_length(amino acids)=814AA_BP=123 MYGKGKSNSSAVPSDSQAREKLALYVYEYLLHVGAQKSAQTFLSEIRWEKNITLGEPPGFLHSWWCVFWDLYCAAPERRETCEHSSEAKA FHDYSAAAAPSPVLGNIPPGDGMPVGPVPPGFFQRENVIEYKHCLITKNENEEYNLSGTKKNFSSLKDLLNCYQMETVRSDNIIFQFTKC CPPKPKDKSNLLVFRTNGVSDVPTSPTLQRPTHMNQMVFHKIRNEDLIFNESLGQGTFTKIFKGVRREVGDYGQLHETEVLLKVLDKAHR NYSESFFEAASMMSKLSHKHLVLNYGVCVCGDENILVQEFVKFGSLDTYLKKNKNCINILWKLEVAKQLAWAMHFLEENTLIHGNVCAKN ILLIREEDRKTGNPPFIKLSDPGISITVLPKDILQERIPWVPPECIENPKNLNLATDKWSFGTTLWEICSGGDKPLSALDSQRKLQFYED RHQLPAPKWAELANLINNCMDYEPDFRPSFRAIIRDLNSLFTPDYELLTENDMLPNMRIGALGFSGAFEDRDPTQFEERHLKFLQQLGKG NFGSVEMCRYDPLQDNTGEVVAVKKLQHSTEEHLRDFEREIEILKSLQHDNIVKYKGVCYSAGRRNLKLIMEYLPYGSLRDYLQKHKERI DHIKLLQYTSQICKGMEYLGTKRYIHRDLATRNILVENENRVKIGDFGLTKVLPQDKEYYKVKEPGESPIFWYAPESLTESKFSVASDVW SFGVVLYELFTYIEKSKSPPAEFMRMIGNDKQGQMIVFHLIELLKNNGRLPRPDGCPDEIYMIMTECWNNNVNQRPSFRDLALRVDQIRD -------------------------------------------------------------- >86711_86711_6_SSBP2-JAK2_SSBP2_chr5_80809446_ENST00000505980_JAK2_chr9_5069021_ENST00000544510_length(amino acids)=814AA_BP=123 MYGKGKSNSSAVPSDSQAREKLALYVYEYLLHVGAQKSAQTFLSEIRWEKNITLGEPPGFLHSWWCVFWDLYCAAPERRETCEHSSEAKA FHDYSAAAAPSPVLGNIPPGDGMPVGPVPPGFFQRENVIEYKHCLITKNENEEYNLSGTKKNFSSLKDLLNCYQMETVRSDNIIFQFTKC CPPKPKDKSNLLVFRTNGVSDVPTSPTLQRPTHMNQMVFHKIRNEDLIFNESLGQGTFTKIFKGVRREVGDYGQLHETEVLLKVLDKAHR NYSESFFEAASMMSKLSHKHLVLNYGVCVCGDENILVQEFVKFGSLDTYLKKNKNCINILWKLEVAKQLAWAMHFLEENTLIHGNVCAKN ILLIREEDRKTGNPPFIKLSDPGISITVLPKDILQERIPWVPPECIENPKNLNLATDKWSFGTTLWEICSGGDKPLSALDSQRKLQFYED RHQLPAPKWAELANLINNCMDYEPDFRPSFRAIIRDLNSLFTPDYELLTENDMLPNMRIGALGFSGAFEDRDPTQFEERHLKFLQQLGKG NFGSVEMCRYDPLQDNTGEVVAVKKLQHSTEEHLRDFEREIEILKSLQHDNIVKYKGVCYSAGRRNLKLIMEYLPYGSLRDYLQKHKERI DHIKLLQYTSQICKGMEYLGTKRYIHRDLATRNILVENENRVKIGDFGLTKVLPQDKEYYKVKEPGESPIFWYAPESLTESKFSVASDVW SFGVVLYELFTYIEKSKSPPAEFMRMIGNDKQGQMIVFHLIELLKNNGRLPRPDGCPDEIYMIMTECWNNNVNQRPSFRDLALRVDQIRD -------------------------------------------------------------- |
Top |
Fusion Protein Functional Features |
| Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr5:/chr9:) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| SSBP2 | JAK2 |
| FUNCTION: Non-receptor tyrosine kinase involved in various processes such as cell growth, development, differentiation or histone modifications. Mediates essential signaling events in both innate and adaptive immunity. In the cytoplasm, plays a pivotal role in signal transduction via its association with type I receptors such as growth hormone (GHR), prolactin (PRLR), leptin (LEPR), erythropoietin (EPOR), thrombopoietin (THPO); or type II receptors including IFN-alpha, IFN-beta, IFN-gamma and multiple interleukins (PubMed:7615558). Following ligand-binding to cell surface receptors, phosphorylates specific tyrosine residues on the cytoplasmic tails of the receptor, creating docking sites for STATs proteins (PubMed:9618263). Subsequently, phosphorylates the STATs proteins once they are recruited to the receptor. Phosphorylated STATs then form homodimer or heterodimers and translocate to the nucleus to activate gene transcription. For example, cell stimulation with erythropoietin (EPO) during erythropoiesis leads to JAK2 autophosphorylation, activation, and its association with erythropoietin receptor (EPOR) that becomes phosphorylated in its cytoplasmic domain. Then, STAT5 (STAT5A or STAT5B) is recruited, phosphorylated and activated by JAK2. Once activated, dimerized STAT5 translocates into the nucleus and promotes the transcription of several essential genes involved in the modulation of erythropoiesis. Part of a signaling cascade that is activated by increased cellular retinol and that leads to the activation of STAT5 (STAT5A or STAT5B) (PubMed:21368206). In addition, JAK2 mediates angiotensin-2-induced ARHGEF1 phosphorylation (PubMed:20098430). Plays a role in cell cycle by phosphorylating CDKN1B (PubMed:21423214). Cooperates with TEC through reciprocal phosphorylation to mediate cytokine-driven activation of FOS transcription. In the nucleus, plays a key role in chromatin by specifically mediating phosphorylation of 'Tyr-41' of histone H3 (H3Y41ph), a specific tag that promotes exclusion of CBX5 (HP1 alpha) from chromatin (PubMed:19783980). {ECO:0000269|PubMed:12023369, ECO:0000269|PubMed:19783980, ECO:0000269|PubMed:20098430, ECO:0000269|PubMed:21368206, ECO:0000269|PubMed:21423214, ECO:0000269|PubMed:7615558, ECO:0000269|PubMed:9618263}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - Retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| - Not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
Fusion Protein Structures |
| PDB and CIF files of the predicted fusion proteins * Here we show the 3D structure of the fusion proteins using Mol*. AlphaFold produces a per-residue confidence score (pLDDT) between 0 and 100. Model confidence is shown from the pLDDT values per residue. pLDDT corresponds to the model’s prediction of its score on the local Distance Difference Test. It is a measure of local accuracy (from AlphfaFold website). To color code individual residues, we transformed individual PDB files into CIF format. |
| Fusion protein PDB link (fusion AA seq ID in FusionPDB) | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | AA seq | Len(AA seq) |
| PDB file (658) >>>658.pdbFusion protein BP residue: 123 CIF file (658) >>>658.cif | SSBP2 | chr5 | 80809446 | - | JAK2 | chr9 | 5069021 | + | MYGKGKSNSSAVPSDSQAREKLALYVYEYLLHVGAQKSAQTFLSEIRWEK NITLGEPPGFLHSWWCVFWDLYCAAPERRETCEHSSEAKAFHDYSAAAAP SPVLGNIPPGDGMPVGPVPPGFFQRENVIEYKHCLITKNENEEYNLSGTK KNFSSLKDLLNCYQMETVRSDNIIFQFTKCCPPKPKDKSNLLVFRTNGVS DVPTSPTLQRPTHMNQMVFHKIRNEDLIFNESLGQGTFTKIFKGVRREVG DYGQLHETEVLLKVLDKAHRNYSESFFEAASMMSKLSHKHLVLNYGVCVC GDENILVQEFVKFGSLDTYLKKNKNCINILWKLEVAKQLAWAMHFLEENT LIHGNVCAKNILLIREEDRKTGNPPFIKLSDPGISITVLPKDILQERIPW VPPECIENPKNLNLATDKWSFGTTLWEICSGGDKPLSALDSQRKLQFYED RHQLPAPKWAELANLINNCMDYEPDFRPSFRAIIRDLNSLFTPDYELLTE NDMLPNMRIGALGFSGAFEDRDPTQFEERHLKFLQQLGKGNFGSVEMCRY DPLQDNTGEVVAVKKLQHSTEEHLRDFEREIEILKSLQHDNIVKYKGVCY SAGRRNLKLIMEYLPYGSLRDYLQKHKERIDHIKLLQYTSQICKGMEYLG TKRYIHRDLATRNILVENENRVKIGDFGLTKVLPQDKEYYKVKEPGESPI FWYAPESLTESKFSVASDVWSFGVVLYELFTYIEKSKSPPAEFMRMIGND KQGQMIVFHLIELLKNNGRLPRPDGCPDEIYMIMTECWNNNVNQRPSFRD | 814 |
| 3D view using mol* of 658 (AA BP:123) | ||||||||||
 | ||||||||||
Top |
pLDDT score distribution |
| pLDDT score distribution of the predicted wild-type structures of two partner proteins from AlphaFold2 * AlphaFold produces a per-residue confidence score (pLDDT) between 0 and 100. |
JAK2_pLDDT.png  |
| pLDDT score distribution of the predicted fusion protein structures from AlphaFold2 * AlphaFold produces a per-residue confidence score (pLDDT) between 0 and 100. |
SSBP2_JAK2_658_pLDDT.png (AA BP:123) |
Top |
Ramachandran Plot of Fusion Protein Structure |
| Ramachandran plot of the torsional angles - phi (φ)and psi (ψ) - of the residues (amino acids) contained in this fusion protein peptide. |
| Fusion AA seq ID in FusionPDB and their Ramachandran plots |
Top |
Potential Active Site Information |
| The potential binding sites of these fusion proteins were identified using SiteMap, a module of the Schrodinger suite. |
| Fusion AA seq ID in FusionPDB | Site score | Size | D score | Volume | Exposure | Enclosure | Contact | Phobic | Philic | Balance | Don/Acc | Residues |
Top |
Potentially Interacting Small Molecules through Virtual Screening |
| The FDA-approved small molecule library molecules were subjected to virtual screening using the Glide. |
| Fusion AA seq ID in FusionPDB | ZINC ID | DrugBank ID | Drug name | Docking score | Glide gscore |
Top |
| Drug information from DrugBank of the top 20 interacting small molecules. |
| ZINC ID | DrugBank ID | Drug name | Drug type | SMILES | Drug group |
Top |
Biochemical Features of Small Molecules |
| ADME (Absorption, Distribution, Metabolism, and Excretion) of drugs using QikProp(v3.9) |
| ZINC ID | mol_MW | dipole | SASA | FOSA | FISA | PISA | WPSA | volume | donorHB | accptHB | IP | Human Oral Absorption | Percent Human Oral Absorption | Rule Of Five | Rule Of Three |
Top |
Drug Toxicity Information |
| Toxicity information of individual drugs using eToxPred |
| ZINC ID | Smile | Surface Accessibility | Toxicity |
Top |
Fusion Protein-Protein Interaction |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
| Protein-protein interactors with each fusion partner protein in wild-type from validated records (BIOGRID-3.4.160) |
| Gene | PPI interactors |
| JAK2 | PRMT5, SOCS1, PPIA, IL12RB2, EPOR, FYN, STAT5A, STAT5B, SH2B2, CXCR4, DNAJA3, HSPA8, TEC, PTPN12, PTK2, CSF2RB, GHR, VAV1, SIRPA, IRS1, BRCA1, GRB2, EGFR, PTK2B, PTPN11, TNFRSF1A, SOCS3, PTPN6, LYN, HTR2A, ERBB2, ELP2, KIT, RAF1, SH2B1, IL5RA, PPP2R1B, IFNGR1, IFNGR2, CCR5, PRLR, IL6ST, SHC1, GRB10, TUB, TSHR, STAT3, INSR, STAM, PTPN1, STAM2, IL2RB, CTLA4, ALK, IKBKG, FGFR1, STAT1, HSP90AA1, HSP90AB1, ASB2, SKP2, GTF2I, HIST3H3, HIST2H3C, CDKN1B, VHL, PIK3R1, MAP3K5, AGTR1, PTAFR, JAK2, IL4R, IL2RG, PPP1CC, ERBB3, CALM1, SRC, JAK3, PLCG1, HES1, HES5, Ifngr1, ASS1, RBMX, TRAF6, EZH2, DTX3L, EMD, KPNB1, NAP1L1, RCN1, SLC2A1, UBP1, ARL11, HSFY1, HDAC6, HNRNPL, CBL, RNF123, Lmo4, GOLPH3, IGF1R, PARP9, LNX1, LDOC1, CSK, MPL, CUL4A, CUL4B, M, JAK1, AMY1C, BPIFA2, ARHGAP18, BACH1, IGHA2, HMMR, MUC7, CST2, IGJ, PBK, MUC5B, SPRR3, ZG16B, VCP, |
| SSBP2 | EWSR1, LDB1, IL36RN, TAL1, LMO2, TRIM33, DYRK2, CDK6, BAG3, TOM1, LDB2, LMX1B, IDI2, ISL2, ISL1, SSBP4, SSBP3, CLEC18A, LMO4, LHX4, LHX6, PIN1, ARHGAP22, ARHGEF10, CAMK2A, FPR1, RRD1, CBFA2T3, NABP1, INTS3, MYH9, ACACA, PC, MCCC2, MCCC1, EP300, PYGO1, BCL9, ORC6, BCL9L, LHX3, MFAP4, LMO1, LMO3, PICK1, VIM, S100A7A, HLA-DRB1, HMOX1, NDRG2, LCP1, IGHG1, IGHG2, TYMP, HIST1H2AG, HLA-DRA, PPL, IL36G, HIST1H1B, NDRG1, IVL, TREX2, IL1RN, GLUL, EVPL, SERPINA1, MNDA, TF, TRIM29, SERPINB3, SERPINB4, SERPINB2, C3, HLA-DQB1, HLA-DPB1, LGALS7B, FGB, SERPINB7, CBR1, ALOX15, IGKC, STAT3, SULT2B1, CALML3, PYCARD, CALML5, IGLL5, H2AFY, T, GATA2, LHX1, LHX2, LHX8, TEAD1, TLX1, |
| Protein-protein interactors based on sequence similarity (STRING) |
| Gene | STRING network |
| SSBP2 |  |
| JAK2 |  |
| - Retained interactions in fusion protein (protein functional feature from UniProt). |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost interactions due to fusion (protein functional feature from UniProt). |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs to SSBP2-JAK2 |
| Drugs used for this fusion-positive patient. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Drug | Source | PMID |
Top |
Related Diseases to SSBP2-JAK2 |
| Diseases that have this fusion gene. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Disease | Source | PMID |
| SSBP2 | JAK2 | Gastric Adenocarcinoma | MyCancerGenome | |
| SSBP2 | JAK2 | Glioblastoma | MyCancerGenome | |
| SSBP2 | JAK2 | Invasive Breast Carcinoma | MyCancerGenome | |
| SSBP2 | JAK2 | Acute Myeloid Leukemia | MyCancerGenome | |
| SSBP2 | JAK2 | Anal Squamous Cell Carcinoma | MyCancerGenome |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Hgene | SSBP2 | C0005586 | Bipolar Disorder | 1 | CTD_human |
| Hgene | SSBP2 | C0005587 | Depression, Bipolar | 1 | CTD_human |
| Hgene | SSBP2 | C0024713 | Manic Disorder | 1 | CTD_human |
| Hgene | SSBP2 | C0033578 | Prostatic Neoplasms | 1 | CTD_human |
| Hgene | SSBP2 | C0338831 | Manic | 1 | CTD_human |
| Hgene | SSBP2 | C0376358 | Malignant neoplasm of prostate | 1 | CTD_human |
| Tgene | JAK2 | C0032463 | Polycythemia Vera | 12 | CTD_human;ORPHANET;UNIPROT |
| Tgene | JAK2 | C0040028 | Thrombocythemia, Essential | 10 | CTD_human;ORPHANET |
| Tgene | JAK2 | C0001815 | Primary Myelofibrosis | 9 | CGI;CTD_human;GENOMICS_ENGLAND;ORPHANET |
| Tgene | JAK2 | C3489628 | Thrombocytosis, Autosomal Dominant | 8 | CTD_human |
| Tgene | JAK2 | C0019154 | Hepatic Vein Thrombosis | 3 | CTD_human;ORPHANET |
| Tgene | JAK2 | C0856761 | Budd-Chiari Syndrome | 3 | CTD_human;ORPHANET |
| Tgene | JAK2 | C0009324 | Ulcerative Colitis | 2 | CTD_human |
| Tgene | JAK2 | C0027022 | Myeloproliferative disease | 2 | CTD_human |
| Tgene | JAK2 | C0151744 | Myocardial Ischemia | 2 | CTD_human |
| Tgene | JAK2 | C0836924 | Thrombocytosis | 2 | CTD_human |
| Tgene | JAK2 | C3281125 | THROMBOCYTHEMIA 3 | 2 | UNIPROT |
| Tgene | JAK2 | C0000786 | Spontaneous abortion | 1 | CTD_human |
| Tgene | JAK2 | C0000822 | Abortion, Tubal | 1 | CTD_human |
| Tgene | JAK2 | C0006663 | Calcinosis | 1 | CTD_human |
| Tgene | JAK2 | C0007873 | Uterine Cervical Neoplasm | 1 | CTD_human |
| Tgene | JAK2 | C0018824 | Heart valve disease | 1 | CTD_human |
| Tgene | JAK2 | C0019207 | Hepatoma, Morris | 1 | CTD_human |
| Tgene | JAK2 | C0019208 | Hepatoma, Novikoff | 1 | CTD_human |
| Tgene | JAK2 | C0021368 | Inflammation | 1 | CTD_human |
| Tgene | JAK2 | C0023418 | leukemia | 1 | CTD_human |
| Tgene | JAK2 | C0023467 | Leukemia, Myelocytic, Acute | 1 | CGI;CTD_human;UNIPROT |
| Tgene | JAK2 | C0023893 | Liver Cirrhosis, Experimental | 1 | CTD_human |
| Tgene | JAK2 | C0023904 | Liver Neoplasms, Experimental | 1 | CTD_human |
| Tgene | JAK2 | C0025472 | Mesenteric Vascular Occlusion | 1 | CTD_human |
| Tgene | JAK2 | C0026998 | Acute Myeloid Leukemia, M1 | 1 | CTD_human |
| Tgene | JAK2 | C0032461 | Polycythemia | 1 | CTD_human |
| Tgene | JAK2 | C0032962 | Pregnancy Complications | 1 | CTD_human |
| Tgene | JAK2 | C0033578 | Prostatic Neoplasms | 1 | CTD_human |
| Tgene | JAK2 | C0040038 | Thromboembolism | 1 | CTD_human |
| Tgene | JAK2 | C0042487 | Venous Thrombosis | 1 | CTD_human |
| Tgene | JAK2 | C0086404 | Experimental Hepatoma | 1 | CTD_human |
| Tgene | JAK2 | C0149871 | Deep Vein Thrombosis | 1 | CTD_human |
| Tgene | JAK2 | C0263628 | Tumoral calcinosis | 1 | CTD_human |
| Tgene | JAK2 | C0376358 | Malignant neoplasm of prostate | 1 | CTD_human |
| Tgene | JAK2 | C0400966 | Non-alcoholic Fatty Liver Disease | 1 | CTD_human |
| Tgene | JAK2 | C0521174 | Microcalcification | 1 | CTD_human |
| Tgene | JAK2 | C1527405 | Erythrocytosis | 1 | CTD_human |
| Tgene | JAK2 | C1879321 | Acute Myeloid Leukemia (AML-M2) | 1 | CTD_human |
| Tgene | JAK2 | C3241937 | Nonalcoholic Steatohepatitis | 1 | CTD_human |
| Tgene | JAK2 | C3495676 | Anorectal Malformations | 1 | GENOMICS_ENGLAND |
| Tgene | JAK2 | C3830362 | Early Pregnancy Loss | 1 | CTD_human |
| Tgene | JAK2 | C4048328 | cervical cancer | 1 | CTD_human |
| Tgene | JAK2 | C4303761 | Familial thrombocytosis | 1 | ORPHANET |
| Tgene | JAK2 | C4552766 | Miscarriage | 1 | CTD_human |
Copyright 2021-Present -The University of Texas Health Science Center at Houston (UTHealth)
Web File Viewing | Emergency Information |Campus Carry|Site Policies